Company intelligence / Profile preview
Codagenix
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
Overview
Codagenix has advanced multiple live attenuated vaccine candidates into clinical trials. Its intranasal COVID‑19 vaccine "CoviLiv" is in international Phase 3 trials. RSV and influenza vaccines are in Phase 1 studies with promising preclinical results. The dengue vaccine program is advancing toward first-in-human studies with recent DoD funding support. Early oncology programs are expanding indications for solid tumor virotherapeutics.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Live attenuated viruses (vaccines and therapeutics)Oncolytic viruses (immuno-oncology)
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Codagenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Codagenix.